Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.47 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.47 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 4/20 | 0.47 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147914 | 1.00 | ALOX15 (0.52) | ALOX15BLMKDM4EMAPTTHRB | |
| SCHEMBL287578 | 0.98 | ALOX15 (0.53) | ALOX15BLMKDM4EMAPTTHRB | |
| SCHEMBL287577 | 0.98 | ALOX15 (0.53) | ALOX15BLMKDM4EMAPTTHRB | |
| SCHEMBL6026388 | 0.98 | ALOX15 (0.53) | ALOX15BLMKDM4EMAPTTHRB | |
| SCHEMBL6445997 | 0.98 | ALOX15 (0.53) | ALOX15BLMKDM4EMAPTTHRB | |
| SCHEMBL7048124 | 0.96 | ALOX15 (0.52) | ALOX15BLMKDM4EMAPTTHRB | |
| Hydrochloric Acid SCHEMBL28715898 | 0.96 | ALOX15 (0.52) | ALOX15BLMKDM4EMAPTTHRB | |
| Hydrochloric Acid SCHEMBL28715899 | 0.96 | ALOX15 (0.52) | ALOX15BLMKDM4EMAPTTHRB | |
| SCHEMBL31436738 | 0.96 | ALOX15 (0.52) | ALOX15BLMKDM4EMAPTTHRB | |
| SCHEMBL27401047 | 0.96 | ALOX15 (0.52) | ALOX15BLMKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190133924-A1 | Alcohol-Resistant Formulations | CIMA LABS INC (US) | 2019-05-09 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-6986901-B2 | Gastrointestinal compositions | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-17 | — | — | US | claimed |
| EP-1549302-A1 | GASTROINTESTINAL COMPOSITIONS COMPRISING GABA DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-07-06 | — | — | EP | claimed |
| US-20050136127-A1 | Trimebutine and/or fedotozine combined with laxatives, antidiarrheals, antibiotics, antiulceratives, gastric secretion inhibitors, peristalitc stimulants, serotonin (5HT3) receptor antagonists, serotonin (5HT4) receptor agonists and/or selective serotonin reuptake inhibitors | MCNEIL-PPC, INC | 2005-06-23 | — | — | US | claimed |
| EP-1531801-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OR MATRIX METALLOPROTEINASE-13 WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 THAT IS NOT CELECOXIB OR VALDECOXIB | Warner-Lambert Company LLC (US) | 2005-05-25 | — | — | EP | claimed |
| CN-1332630-A | Oral pharmaceutical composition having therapeutic activity on gastrointestinal disorders | DAE WOONG PHARMA (KR) | 2002-01-23 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000040254-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION HAVING THERAPEUTIC ACTIVITY ON GASTROINTESTINAL DISORDERS | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2000-07-13 | — | — | WO | claimed |
| US-5908824-A | DISPERSED HOMOGENEOUSLY IN AND ADSORBED HOMOGENEOUSLY ONTO A MUCOSA PROTECTING AND/OR TISSUE REPAIRING AGENT | DOTT RESEARCH LABORATORY (JP) | 1999-06-01 | — | — | US | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0770390-A1 | Nasally administrable compositions containing physiologically active peptides | DOTT RESEARCH LABORATORY (JP) | 1997-05-02 | — | — | EP | claimed |
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050136127-A1 | Trimebutine and/or fedotozine combined with laxatives, antidiarrheals, antibiotics, antiulceratives, gastric secretion inhibitors, peristalitc stimulants, serotonin (5HT3) receptor antagonists, serotonin (5HT4) receptor agonists and/or selective serotonin reuptake inhibitors | HTR4, HTR6, SLC6A4 | ALOX15 2709/4885BLM 2495/4885KDM4E 2148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.